Foundation News

The Crohn’s & Colitis Foundation, the nation’s leading nonprofit organization focused on research and patient support for inflammatory bowel disease (IBD), is joining forces with the Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to increase awareness of opportunities for accessing some reduced-price essential IBD medications.  

Alan Moss, MD, a renowned clinician-scientist, begins his tenure today as the Chief Scientific Officer at the Crohn’s & Colitis Foundation. His prior roles include serving as the Director of the Crohn’s & Colitis Program at Boston Medical Center (BMC) and Professor of Medicine at Boston University (BU). In his clinical practice, Dr. Moss has cared for IBD patients from underserved, immigrant, and unhoused populations.

UnitedHealthcare (UHC) has delayed implementing a new policy that would have required prior authorization for most physician-prescribed endoscopy and colonoscopy procedures, which was slated to begin June 1. This decision comes after UHC faced significant backlash from the GI community, and a rally was led by the Crohn's & Colitis Foundation alongside IBD healthcare professionals and patients outside UHC’s Minnesota headquarters on May 31. The Foundation was invited to meet with UHC to discuss the policy after the rally.

Using collective data made available by IBD Plexus, researchers’ findings advance the possibility of microbiome-based personalized medicine for IBD treatment.

Legislation will give patients and their doctors a process to seek exception to Step Therapy requirements that may delay necessary care

The Crohn's & Colitis Foundation advocates for reform in the Pharmacy Benefit Manager (PBM) industry due to the negative impact it has on patients' access to medicine.

Last week, in an unprecedented decision, a Texas federal judge invalidated the Food and Drug Administration’s (FDA) approval of a drug that was approved by the agency in 2000.

April 3, 2023, New York, NY – Last week, the U.S. Equal Employment Opportunity Commission (EEOC) sued Walmart for firing a North Carolina employee with Crohn’s disease after the company allegedly refused to grant her disability-related leave.

Since 2017, IBD Ventures Has Invested Over $9 Million In R&D Funding to Portfolio Companies

New York, NY, March 14, 2023 – Early life stress (ELS) in mice can disrupt the gut immune response, leading to longer-lasting intestinal inflammation and a worsened future disease state than control mice not exposed to ELS, according to a new study published in Inflammatory B